Importance  Peripheral facial nerve (Bell) palsy has been reported and widely suggested as a possible adverse effect of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Israel is currently the leading country in vaccination rates per capita, exclusively using the BNT162b2 vaccine, and all residents of Israel are obligatory members of a national digital health registry system. These factors enable early analysis of adverse events.

Objective  To examine whether the BNT162b2 vaccine is associated with an increased risk of acute-onset peripheral facial nerve palsy.

Design, Setting, and Participants  This case-control study was performed from January 1 to February 28, 2021, at the emergency department of a tertiary referral center in central Israel. Patients admitted for facial nerve palsy were matched by age, sex, and date of admission with control patients admitted for other reasons.

Exposures  Recent vaccination with the BNT162b2 vaccine.

Main Outcomes and Measures  Adjusted odds ratio for recent exposure to the BNT162b2 vaccine among patients with acute-onset peripheral facial nerve palsy. The proportion of patients with Bell palsy exposed to the BNT162b2 vaccine was compared between groups, and raw and adjusted odds ratios for exposure to the vaccine were calculated. A secondary comparison with the overall number of patients with facial nerve palsy in preceding years was performed.

Results  Thirty-seven patients were admitted for facial nerve palsy during the study period, 22 (59.5%) of whom were male, and their mean (SD) age was 50.9 (20.2) years. Among recently vaccinated patients (21 [56.7%]), the mean (SD) time from vaccination to occurrence of palsy was 9.3 (4.2 [range, 3-14]) days from the first dose and 14.0 (12.6 [range, 1-23]) days from the second dose. Among 74 matched controls (2:1 ratio) with identical age, sex, and admittance date, a similar proportion were vaccinated recently (44 [59.5%]). The adjusted odds ratio for exposure was 0.84 (95% CI, 0.37-1.90; P = .67). Furthermore, analysis of the number of admissions for facial nerve palsy during the same period in preceding years (2015-2020) revealed a relatively stable trend (mean [SD], 26.8 [5.8]; median, 27.5 [range, 17-35]).

Conclusions and Relevance  In this case-control analysis, no association was found between recent vaccination with the BNT162b2 vaccine and risk of facial nerve palsy.
COVID-19 is caused by SARS-CoV-2, and immunity can be achieved either by native or preventive immunization of the population. Thus far, the US Food and Drug Administration has issued an emergency use authorization for 3 novel COVID-19 vaccines.1 On December 11, 2020, the BNT162b2 (Pfizer-BioNTech) vaccine was the first to achieve this authorization, and millions of people worldwide have been vaccinated with it.2

Peripheral facial nerve palsy has been reported and widely suggested as a possible adverse effect of the BNT162b2 vaccine.3,4 This was initially prompted by the imbalance in peripheral facial nerve palsy cases reported in the original efficacy trial published in December 2019.10,11 Peripheral facial nerve palsy was reported in 4 cases among the vaccinated participants and none of the controls.10,11 Since then, several case reports and commentaries4-9 and much media attention have been devoted to the subject,3,5,6,12,13 yet robust evidence is scarce.

On December 19, 2020, Israel launched a national vaccination program. Israel is the leading country in vaccination rates per capita, with approximately 92% and 85% of the population older than 50 years immunized with the first and second doses, respectively, as of March 1, 2021.14 At present, vaccination in Israel is promoted exclusively with the BNT162b2 vaccine. All residents of Israel are members of a national digital health registry system. These factors provide a unique opportunity to perform an early real-world analysis of adverse events due to the BNT162b2 vaccine and report on an association or the lack thereof regarding peripheral facial nerve palsy after vaccination.

Methods

This study adhered to the tenets of the Declaration of Helsinki15 and was approved by the institutional review board of the Shamir Medical Center. Owing to its retrospective nature, a waiver of informed consent was granted. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Design and Patient Population

The BNT162b2 vaccine was given emergency use authorization by the US Food and Drug Administration in early December 2020. It has been authorized for all individuals older than 16 years and is injected in 2 doses separated by a 21-day interval.

We conducted a case-control study examining the association between exposure to the BNT162b2 vaccine and facial nerve palsy. Cases were defined as patients who were admitted to the emergency department of a single tertiary referral center in Israel (Shamir Medical Center [formerly Assaf Harohef], Tzrifin) and were diagnosed with new-onset peripheral facial nerve palsy from January 1 to February 28, 2021. In Israel, it is standard practice to refer all patients with new-onset peripheral nerve palsy for evaluation in the emergency department. Data were collected by a computerized hospital system according to International Classification of Diseases, Ninth Revision, code 351.0 (Bell palsy). We retrospectively reviewed each medical record and manually recorded rates and timing of vaccination with the BNT162b2 vaccine. Included were all patients who were older than 18 years and of any medical status. Controls were patients who had been admitted to the same emergency department for any reason other than facial nerve palsy and were matched for age, sex, and admission date within 48 hours.

Controls were matched for date of admission for 2 reasons. First, seasonality was found to be a risk factor for peripheral nerve palsy, and matching enabled us to exclude this as a possible bias between groups. Second, vaccines were being rolled out in Israel during this time, and later admission predisposed a given patient to a higher chance of being vaccinated. Matching for admission date was a way to ensure that timing was not a possible factor for bias.

Two controls were matched for each case and were randomly selected. In both groups, the percentage of patients exposed to the BNT162b2 vaccine (first or second dose) within the previous 30 days was calculated and the adjusted and unadjusted odds ratios (ORs) for exposure were compared with corresponding 95% CIs. Age, sex, and seasonality are risk factors for facial nerve palsy and are inherently controlled for by the study design; however, existence of immune- or inflammatory-related disorders, diabetes, and a previous episode of peripheral nerve palsy are also implicated as possible risk factors. These factors were extracted, and an adjusted OR controlling for these factors was also calculated.

As a secondary analysis, all cases of facial nerve palsy during the same period (January to February) in the 6 preceding years were extracted according to International Classification of Diseases, Ninth Revision, codes and compared with 2021. The months of January and February were selected because the national vaccination campaign in Israel began on December 19, 2020, and by March 1, 2021, more than 92% of the population older than 50 years was already vaccinated with the first dose.14 Thus, early postvaccination adverse events should be evident during this period. For this analysis, the data are presented as they are and the overall trend is presented without statistical analyses.

Statistical Analysis

Statistical analysis was performed using IBM SPSS Statistics, version 25 (IBM Corp). Categorical variables such as sex and
existence of diabetes were compared using the χ² test. Continuous variable distributions were tested for normality by the Shapiro-Wilk test. Independent 2-tailed \( t \) tests were conducted for continuous variables with a normal distribution and the Mann-Whitney test for continuous variables with a non-normal distribution. The OR for exposure to the vaccine was calculated with the corresponding 95% CI. Two-sided \( P < .05 \) was considered statistically significant. For sample calculation, a case-control model was used with a CI of 0.95 and power was set at 80%. Assuming an exposed proportion of 0.6 among the controls and an expected OR of 4.00, the total sample size needed (in both groups) to detect a significant association was calculated to be 88 patients. Sample size calculations were performed using MedCalc software, version 17 (MedCalc Software Ltd).

### Results

During the study period, a total of 37 patients were admitted for an acute-onset facial nerve palsy. The mean (SD) patient age was 50.9 (20.2) years; 22 (59.5%) were male and 15 (40.5%) were female. Most of the patients were discharged on the same day, and only 2 were admitted for further evaluation. Of the 37 patients, 4 (10.8%) had diabetes, 2 (5.4%) had immune- or inflammatory-associated disorders (familial Mediterranean fever and psoriasis), and 2 (5.4%) had a previous episode of peripheral facial nerve palsy. A detailed description of the cases is provided in Table 1. Comparing recently vaccinated (21 of 37 [56.7%]) with unvaccinated (16 of 37 [43.2%]) patients showed no meaningful difference in age (mean [SD], 55.5 [19.2] vs 44.9 [20.5] years; \( P = .12 \)) or sex (13 [61.9%] male vs 9 [56.3%] male; \( P = .73 \)). Among recently vaccinated patients who received only the first dose, the mean (SD) time from vaccination to occurrence of facial nerve palsy was 9.3 (4.2 [range, 3-14]) days; among those who completed the vaccination process with the second dose (10 of 37 [27.0%]), the mean (SD) time from vaccination was 14.0 (12.6 [range, 1-23]) days.

For each patient admitted with a case of new-onset peripheral facial nerve palsy, 2 matched controls were randomly selected. No meaningful differences were seen between the controls and cases in terms of a diagnosis of diabetes (4 of 37 [10.8%] among cases vs 15 of 74 [20.3%] among controls; difference, 9.5% [95% CI, −6.4% to 21.8%]), rates of immune- or inflammatory-related disorders (2 of 37 [5.4%] among cases vs 3 of 74 [4.1%] among controls; difference, 1.3% [95% CI, −6.8% to 13.9%]), and a previous episode of peripheral nerve palsy (2 of 37 [5.4%] among cases vs 0 of 74 among controls; difference, 5.4% [95% CI, −0.9% to 17.7%]). Overall, 21 of 37 individuals (56.8%) with facial nerve palsy were recently vaccinated with the first or second dose of the BNT162b2 vaccine, compared with 44 of 74 (59.5%) in the control group (Table 2). The unadjusted OR for exposure to the vaccine among cases was 0.90 (95% CI, 0.40-1.99; \( P = .79 \)).

After adjusting for existence of immune- or inflammatory-related disorders, diabetes, and a previous episode of peripheral nerve palsy, the OR for exposure to the vaccine among cases was 0.84 (95% CI, 0.37-1.90; \( P = .67 \)). In addition, we compared the overall number of patients with acute-onset facial nerve palsy with that of preceding years, before the advent of the COVID-19 pandemic or vaccine. Table 3 shows the number of cases of facial nerve palsy admitted during January and
lished in December of 2020, peripheral facial nerve palsy dramatic increase in cases should have been evident. Even a small association of the vaccine with facial nerve palsy, with regard to the messenger RNA (mRNA–1273 [Moderna] was reported in 4 cases among the vaccinated participants. This seeming small detail sparked considerable attention. Several opinion articles and case reports have been published on the subject, and media attention has been extensive. This attention could influence vaccination rates in addition to the effort of global public health in eliminating infection rates.

Previously, facial nerve palsy has been reported as a possible adverse event in other vaccinations, including influenza vaccine and meningococcal conjugate vaccine. The mechanism for this is thought to involve the additive adjuvants that initiate an immunomodulatory response within the cells. However, the mRNA-based vaccines produced by Pfizer-BioNTech and Moderna use a different mechanism without adjuvants. An immune response is nonetheless a necessary component for efficacy and, via either mimicry of host molecules or bystander activation of dormant autoreactive T cells, a theoretical association with facial nerve palsy could occur. Another possibility is that the BNT162b2 vaccine might induce innate immune activation and production of interferon proteins by a combined effect of mRNA and lipids. Facial nerve palsy has been reported as a possible rare complication of interferon therapy.

### Discussion

In this study, occurrence of acute-onset facial nerve palsy was evaluated for an association with recent SARS-CoV-2 vaccination with the BNT162b2 vaccine. In a case-control comparison with controls matched for age, sex, and date of admission, no association between facial nerve palsy and vaccination status was observed. In addition, when comparing the number of patients admitted for facial nerve palsy during the same period in preceding years, a similar volume of admissions is seen. These results are noteworthy given that the first vaccination occurred in Israel on December 19, 2020, and by March 1, 2021, more than 92% of the population of Israel older than 50 years was already vaccinated with the first dose. Given even a small association of the vaccine with facial nerve palsy, a dramatic increase in cases should have been evident.

In the original BNT162b2 safety and efficacy trial published in December of 2020, peripheral facial nerve palsy was reported in 4 cases among the vaccinated participants and none of the controls. Similar results were published later with regard to the messenger RNA (mRNA–1273 [Moderna] SARS-CoV-2 vaccine. The authors reported 3 participants who developed Bell palsy in the vaccine group, compared with only 1 participant in the placebo group during the observation period of the trial (~28 days after injection). This seemingly small detail sparked considerable attention. Several opinion articles and case reports have been published on the subject, and media attention has been extensive. This attention could influence vaccination rates in addition to the effort of global public health in eliminating infection rates.

### Limitations

This study has several limitations. First, only the effects of recent vaccination were evaluated, and long-term outcomes are currently unavailable for analysis. Second, we examined only facial nerve palsy as an outcome. Third, all patients received the BNT162b2 vaccine, and results cannot be generalized to other SARS-CoV-2 vaccine types. Finally, the secondary analysis of overall patients admitted compared with preceding years could be biased by unmeasurable factors such as referral patterns.

### Conclusions

In this case-control study, no association between acute facial nerve palsy and recent vaccination with the BNT162b2 vaccine was observed. In addition, despite rapid and extensive vaccination of the population, a similar volume of admissions for facial nerve palsy was seen compared with the same period in preceding years.

### Table 2. Distribution of Vaccinated and Nonvaccinated Patients Among Cases With New-Onset Peripheral Facial Nerve Palsy and Matched Controls

<table>
<thead>
<tr>
<th>Patient group</th>
<th>No. of cases</th>
<th>No. of controls</th>
<th>Total No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccinated</td>
<td>21</td>
<td>44</td>
<td>65</td>
</tr>
<tr>
<td>Nonvaccinated</td>
<td>16</td>
<td>30</td>
<td>46</td>
</tr>
<tr>
<td>Total</td>
<td>37</td>
<td>74</td>
<td>111</td>
</tr>
</tbody>
</table>

### Table 3. Facial Nerve Palsy Cases in January and February 2021 and During the Same Period in the 6 Preceding Years

| Year | No. of cases | Age, mean (SD), y | Male, No. (%)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>37</td>
<td>74.0 (5.8)</td>
<td>111</td>
</tr>
</tbody>
</table>

### References


Bell Palsy and COVID-19
Overcoming the Fear of “Known Unknowns”

C. W. David Chang, MD

The emergency use authorization of the first 2 messenger RNA COVID-19 vaccines in the US has given rise to a fascinating study of otolaryngological medical and social influence issues. As of May 1, 2020, the COVID-19 pandemic has resulted in more than 151 million cases and 3.2 million deaths worldwide. In the US, these statistics include 32.4 million cases (9757 per 100 000 population) and 576 000 deaths (173 per 100 000 population).1 The cold sterility of numbers is difficult to put into context. Likewise, when Pfizer-BioNTech and Moderna revealed cases of Bell palsy in their vaccine trials, concerns grew regarding the potential of the vaccines to cause Bell palsy. Numbers thrown out to either demonstrate or refute safety are likewise difficult for the public to contextualize. Epidemiologically, linking the vaccine with an adverse event requires accurate estimation of event incidence in association with the vaccine, comparison with a nonvaccinated group, and understanding of the background incidence.

Historical background rates for safety surveillance provide some context, but their use is not without caveats. Rates vary not only by patient factors such as age (older age associated with higher incidence) and sex (mixed results), but also by geography, time, and collection method (traditional vs electronic medical record [EMR] review, hospital-based vs general practice–based vs “door-to-door” assessment).

Although many publications cite an incidence of 11.0 to 51.9 per 100 000 person-years,2 these rates can vary widely. For example, a large study in the UK using Clinical Practice Research Datalink (one of the world’s largest longitudinal databases containing EMRs from more than 640 UK general practices) identified 14 460 patients with Bell palsy, an overall incidence of 37.7 per 100 000 person-years from 2001 to 2012. Only new cases of Bell palsy were included.3 In contrast, an Israeli study using EMR data from a health maintenance organization from 2003 to 2012 identified 4463 patients with an overall incidence of 87.0 per 100 000 person-years.4 Further confounding background rates, the COVID-19 pandemic itself has been theorized to affect the incidence of Bell palsy, with mixed findings.

In this issue of JAMA Otolaryngology, Tamaki et al4 queried a large-scale EMR database contributed to by 41 health care organizations during a 1-year span to look more specifically at rates of Bell palsy in patients with a COVID-19 diagnosis. Of 348 088 identified patients with COVID-19, 284 had a diagnosis of Bell palsy within 8 weeks of COVID-19 diagnosis: 153 patients had new-onset Bell palsy, whereas 131 had recurrent Bell palsy. The authors translate this to an 8-week incidence of 82 per 100 000 patients with COVID-19. However, if using a crude analysis and assuming a prepandemic rate of 40 per 100 000 person-years and no seasonality, Bell palsy would be expected to naturally occur in only 21 of 348 088 patients during an 8-week period. This suggests that COVID-19 could